Fostamatinib (R788) |
| Catalog No.GC11044 |
Fostamatinib (R788) (R788) is the oral prodrug of the active compound R406.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 901119-35-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Fostamatinib (R788) is the oral prodrug of the active compound R406, a relatively selective small molecule inhibitor of Syk [1]. R406 is a competitive inhibitor for ATP binding to the Syk catalytic domain (Ki = 30 nM), and inhibits Syk kinase activity in vitro with an IC50 of 41 nM [2].
Fostamatinib (R788) induced a time- and dose-dependent reduction in viability of WaldenstrÖm macroglobulinemia (WM) MWCL-1 and BWCM.1 cells, with IC50 that were in the physiologically relevant range of approximately 0.25 and 1 µM, respectively, at 3 days [3]. Fostamatinib (R788) greatly inhibited the proliferation of six HPV-negative HNSCC cell lines in vitro [4].
Fostamatinib (R788) (80 mg/kg/d, 21d) significantly prolonged the survival of mice challenged with the leukemia lines TCL1-551 and TCL1-870 [5]. Fostamatinib (R788)(80 mg/kg/d, 7d) has shown efficacy in murine models of non-Hodgkin`s lymphoma (NHL), reducing tumour burden and prolonging survival in treated mice [6]. A single oral dose of R788 10 mg/kg or 20 mg/kg: Cmax = 2600 ng/ml and 6500 ng/ml respectively (observed at 1 hour), t1/2 = 4.2 hours in Louvain rats [7].
References:
[1]. McAdoo S P, Tam F W K. Fostamatinib disodium[J]. Drugs of the Future, 2011, 36(4): 273.
[2]. Braselmann S, Taylor V, Zhao H, et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation[J]. Journal of Pharmacology and Experimental Therapeutics, 2006, 319(3): 998-1008.
[3]. Kuiatse I, Thomas S K, Weber D M, et al. Inhibition of spleen tyrosine kinase with fostamatinib shows pre-clinical activity against models of Waldenström macroglobulinemia[J]. Blood, 2012, 120(21): 3723.
[4]. Tian G, Fu Y, Zhang D, et al. Identification of four key prognostic genes and three potential drugs in human papillomavirus negative head and neck squamous cell carcinoma[J]. Cancer cell international, 2021, 21(1): 1-18.
[5]. Suljagic M, Longo P G, Bennardo S, et al. The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ-TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling[J]. Blood, The Journal of the American Society of Hematology, 2010, 116(23): 4894-4905.
[6]. Young R M, Hardy I R, Clarke R L, et al. Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target[J]. Blood, The Journal of the American Society of Hematology, 2009, 113(11): 2508-2516.
[7]. Pine P R, Chang B, Schoettler N, et al. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor[J]. Clinical immunology, 2007, 124(3): 244-257.
Average Rating: 5 (Based on Reviews and 37 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *